Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628988 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04628988 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 6 participants.
The verdict
NCT04628988, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, positron emission tomography (PET) imaging Proof of Biology (POB) study to determine whether CC -90011 reverses, by the induction of androgen receptor (AR) expression, the castration resistance, due to lineage switch, in participants with mCRPC that have failed enzalutamide as last prior therapy. This study aims to assess whether CC-90011 can induce AR expression and, consequently, re-sensitize tumors to anti-hormonal therapy.
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG CC-90011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628988
The ClinicalTrials.gov registry entry for NCT04628988 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT04628988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04628988 about?
NCT04628988 is a clinical study titled "A Study of CC-90011 and Comparators in Participants With Prostate Cancer". This is an open-label, positron emission tomography (PET) imaging Proof of Biology (POB) study to determine whether CC -90011 reverses, by the induction of androgen receptor (AR) expression, the castration resistance, due to lineage switch, in participants with mCRPC that have failed enzalutamide as...
What is the current status of trial NCT04628988?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-07-28. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04628988?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), CC-90011 (DRUG).
Who is sponsoring clinical trial NCT04628988?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.